Table 1.
Patient characteristics
| Total patients | n = 268 (%) |
|---|---|
| Median age, years (IQR) | 71.0 (11.0) |
| Race | |
| Caucasian | 227 (85) |
| African American/Black | 24 (9) |
| Other | 17 (6) |
| Comorbidity | |
| Diabetes | 49 (18) |
| Smoking | 28 (10) |
| Prostate volume, cm3 (IQR)# | 36.0 (25.0) |
| Bladder volume, cm3 (IQR) | 148.5 (169.2) |
| Cross-sectional rectal area, cm2(IQR) | 7.3 (3.2) |
| Extent of the seminal vesicles, cm (IQR) | 2.7 (0.6) |
| Risk group* | |
| Low | 58 (22) |
| Intermediate | 144 (53) |
| High | 66 (25) |
| Androgen deprivation therapy | |
| no | 134 (50) |
| yes | 134 (50) |
| Median duration, months (range) | 7 (1–35) |
| IGRT using fiducial markers | |
| no | 213 (79) |
| yes | 55 (21) |
| Cone down | |
| no | 214 (80) |
| yes+ | 54 (20) |
| Median FU, years (range) | 5 (3–7.7) |
| Patients available in FU periods | |
| Baseline | 268 (100) |
| 3–6 months | 208 (78) |
| 6–12 months | 176 (66) |
| 12–18 months | 184 (69) |
| 18–24 months | 122 (46) |
| 24–36 months | 220 (82) |
| 36–48 months | 236 (88) |
| 48–60 months | 166 (62) |
Abbreviations:
#
information lacking for 11 patients;
*
according to the National Comprehensive Cancer Network (NCCN);
+
cone downs were performed after a median dose of 54 (range, 30.6–72) Gy
IQR=interquartile range;
IGRT=image guided radiation therapy;
FU=follow-up